Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs Cassava Sciences Inc (FLNA) Price & Performance

Diamondback Energy IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs Cassava Sciences Inc — how do they compare? Diamondback Energy Inc trades at $201.5 (market cap $56.48B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Diamondback Energy Inc is far larger — about 1182.8× Cassava Sciences Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FANGFLNA
Market Cap
$56.48B$47.75M
Sector
EnergyHealth
52-Week High
$213.69$4.64
52-Week Low
$134.53$0.87
Enterprise Value
$68.63B-$34.93M
Dividend Yield
2.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $200.97, up 1.01% today, with bullish technical signals and strong earnings beats in Q1 and Q2 2026. The stock benefits from high oil prices, production growth, and a 90% analyst buy rating. Recent news highlights Q2 earnings surpassing estimates, driven by operational efficiency and raised 2026 output guidance. Cash flow from operations improved to $8.76 billion in 2025, though net income margin declined to 8.64%.

The outlook is positive, with a consensus price target of $236.63 offering ~18% upside, supported by debt reduction and Permian Basin strength. Risks include oil price volatility, margin pressure from rising costs, and geopolitical supply disruptions affecting global markets. Institutional inflows, like Balefire LLC's recent purchase, reinforce confidence in growth prospects.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA